{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T06:03:54Z","timestamp":1771049034732,"version":"3.50.1"},"reference-count":61,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018268","name":"Children\u2019s Miracle Network","doi-asserted-by":"crossref","award":["AWD00099248"],"award-info":[{"award-number":["AWD00099248"]}],"id":[{"id":"10.13039\/100018268","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100018268","name":"Children\u2019s Miracle Network","doi-asserted-by":"crossref","award":["AWD16653"],"award-info":[{"award-number":["AWD16653"]}],"id":[{"id":"10.13039\/100018268","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Adeno-associated viral vectors (AAV) are the leading gene therapy in the clinic. AAV9 has been of particular interest due to its wide tropism for multiple tissue types as well as being able to cross the blood-brain barrier and transduce central nervous system tissues. However, effectively and safely targeting extrahepatic tissue following the systemic administration of AAV9 remains a challenge due to high rates of liver transduction and liver toxicity. Thus, a crucial first step in developing a safe AAV9-based vector is to reduce liver targeting. Here we utilized rational design techniques to make five point mutations in the AAV9 capsid. In doing so, we developed a novel AAV9 variant, AAV9-DM, that is characterized by reduced liver tropism as compared to AAV9 and other liver de-targeted AAV9 mutants. We show that AAV9-DM is effective at transducing cells in vivo, resulting in robust transgene expression over a 9-week period. Importantly, the AAV9-DM capsid maintains the ability to transduce non-hepatic tissues with a biodistribution similar to AAV9. This new mutant represents a novel AAV capsid that may be the basis for developing safer therapeutics to target extrahepatic tissue while reducing adverse side effects related to liver transduction.<\/jats:p>","DOI":"10.3390\/cells15040334","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T12:05:46Z","timestamp":1770897946000},"page":"334","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Rationally Designed AAV9-DM Capsid with Minimal Liver Tropism"],"prefix":"10.3390","volume":"15","author":[{"given":"Zoe C.","family":"Nabakowski","sequence":"first","affiliation":[{"name":"Division of Cellular and Molecular Therapy, Department of Pediatrics, University of Florida, College of Medicine, Gainesville, FL 32611, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izabella C.","family":"Jaramillo","sequence":"additional","affiliation":[{"name":"Division of Cellular and Molecular Therapy, Department of Pediatrics, University of Florida, College of Medicine, Gainesville, FL 32611, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Primrose","family":"Tanachaiwiwat","sequence":"additional","affiliation":[{"name":"Division of Cellular and Molecular Therapy, Department of Pediatrics, University of Florida, College of Medicine, Gainesville, FL 32611, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1517-8894","authenticated-orcid":false,"given":"Geoffrey D.","family":"Keeler","sequence":"additional","affiliation":[{"name":"Division of Cellular and Molecular Therapy, Department of Pediatrics, University of Florida, College of Medicine, Gainesville, FL 32611, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1128\/jvi.45.2.555-564.1983","article-title":"Nucleotide sequence and organization of the adeno-associated virus 2 genome","volume":"45","author":"Srivastava","year":"1983","journal-title":"J. Virol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0378-1119(96)00576-8","article-title":"Adeno-associated virus 2-mediated gene transfer in vivo: Organ-tropism and expression of transduced sequences in mice","volume":"190","author":"Ponnazhagan","year":"1997","journal-title":"Gene"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/hum.2015.29017.asr","article-title":"Adeno-Associated Virus: The Naturally Occurring Virus Versus the Recombinant Vector","volume":"27","author":"Srivastava","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_6","unstructured":"(2025, June 11). Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/luxturna."},{"key":"ref_7","unstructured":"(2025, June 11). Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/zolgensma."},{"key":"ref_8","unstructured":"(2025, June 11). Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/hemgenix."},{"key":"ref_9","unstructured":"(2025, June 11). Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/tissue-tissue-products\/elevidys."},{"key":"ref_10","unstructured":"(2025, June 11). Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/roctavian."},{"key":"ref_11","unstructured":"FDA (2024). FDA Approves First Gene Therapy for Treatment of Aromatic L-Amino Acid Decarboxylase Deficiency."},{"key":"ref_12","first-page":"1122","article-title":"Chemical modification of the adeno-associated virus capsid to improve gene delivery","volume":"11","author":"Bouzelha","year":"2019","journal-title":"Chem. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","article-title":"Lethal immunotoxicity in high-dose systemic AAV therapy","volume":"31","author":"Duan","year":"2023","journal-title":"Mol. Ther."},{"key":"ref_14","first-page":"01132","article-title":"Deaths in gene therapy of Duchenne muscular dystrophy and other diseases: Underlying mechanisms and mitigating strategies","volume":"25","author":"Duan","year":"2026","journal-title":"Mol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/med.22036","article-title":"The menace of severe adverse events and deaths associated with viral gene therapy and its potential solution","volume":"44","author":"Kachanov","year":"2024","journal-title":"Med. Res. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.nmd.2023.11.010","article-title":"Continued safety and long-term effectiveness of onasemnogene abeparvovec in Ohio","volume":"34","author":"Waldrop","year":"2024","journal-title":"Neuromuscul. Disord."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"100817","DOI":"10.1016\/j.lanepe.2023.100817","article-title":"Efficacy and safety of onasemnogene abeparvovec in children with spinal muscular atrophy type 1: Real-world evidence from 6 infusion centres in the United Kingdom","volume":"37","author":"Gowda","year":"2024","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s40264-021-01107-6","article-title":"Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy","volume":"44","author":"Day","year":"2021","journal-title":"Drug Saf."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Chan, C., Harris, K.K., Zolotukhin, S., and Keeler, G.D. (2023). Rational Design of AAV-rh74, AAV3B, and AAV8 with Limited Liver Targeting. Viruses, 15.","DOI":"10.3390\/v15112168"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.omtm.2018.03.004","article-title":"A Rationally Engineered Capsid Variant of AAV9 for Systemic CNS-Directed and Peripheral Tissue-Detargeted Gene Delivery in Neonates","volume":"9","author":"Wang","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ymthe.2017.09.001","article-title":"Gene Therapy-Induced Antigen-Specific Tregs Inhibit Neuro-inflammation and Reverse Disease in a Mouse Model of Multiple Sclerosis","volume":"26","author":"Keeler","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.omtm.2022.12.011","article-title":"Induction of antigen-specific tolerance by hepatic AAV immunotherapy regardless of T cell epitope usage or mouse strain background","volume":"28","author":"Keeler","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/sj.gt.3300938","article-title":"Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield","volume":"6","author":"Zolotukhin","year":"1999","journal-title":"Gene Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtm.2018.05.001","article-title":"Helper-free Production of Laboratory Grade AAV and Purification by Iodixanol Density Gradient Centrifugation","volume":"10","author":"Crosson","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jviromet.2006.06.011","article-title":"Quantitation of encapsidated recombinant adeno-associated virus DNA in crude cell lysates and tissue culture medium by quantitative, real-time PCR","volume":"137","author":"Mayginnes","year":"2006","journal-title":"J. Virol. Methods"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.actbio.2015.05.011","article-title":"Effects of delayed delivery of dexamethasone-21-phosphate via subcutaneous microdialysis implants on macrophage activation in rats","volume":"23","author":"Keeler","year":"2015","journal-title":"Acta Biomater."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.actbio.2014.10.022","article-title":"Localized delivery of dexamethasone-21-phosphate via microdialysis implants in rat induces M(GC) macrophage polarization and alters CCL2 concentrations","volume":"12","author":"Keeler","year":"2015","journal-title":"Acta Biomater."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.omtm.2022.06.013","article-title":"Natural variations in AAVHSC16 significantly reduce liver tropism and maintain broad distribution to periphery and CNS","volume":"26","author":"Smith","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/mt.2008.76","article-title":"Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection","volume":"16","author":"Zincarelli","year":"2008","journal-title":"Mol. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1016\/j.ymthe.2022.11.001","article-title":"Vector genome loss and epigenetic modifications mediate decline in transgene expression of AAV5 vectors produced in mammalian and insect cells","volume":"30","author":"Handyside","year":"2022","journal-title":"Mol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/mt.2010.274","article-title":"Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins","volume":"19","author":"Nathwani","year":"2011","journal-title":"Mol. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1182\/blood-2012-10-462200","article-title":"Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant","volume":"121","author":"McIntosh","year":"2013","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-Associated Virus Vector\u2013Mediated Gene Transfer in Hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Hollidge, B.S., Carroll, H.B., Qian, R., Fuller, M.L., Giles, A.R., Mercer, A.C., Danos, O., Liu, Y., Bruder, J.T., and Smith, J.B. (2022). Kinetics and durability of transgene expression after intrastriatal injection of AAV9 vectors. Front. Neurol., 13.","DOI":"10.3389\/fneur.2022.1051559"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/mt.2011.22","article-title":"Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer","volume":"19","author":"Pulicherla","year":"2011","journal-title":"Mol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"101571","DOI":"10.1016\/j.omtm.2025.101571","article-title":"Directed evolution of liver-detargeted AAV vectors for systemic gene delivery to skeletal muscle and heart","volume":"33","author":"Firnberg","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ymthe.2006.03.014","article-title":"Robust systemic transduction with AAV9 vectors in mice: Efficient global cardiac gene transfer superior to that of AAV8","volume":"14","author":"Inagaki","year":"2006","journal-title":"Mol. Ther."},{"key":"ref_38","first-page":"237","article-title":"Development of genome-modified generation Y (GenY) AAVrh74 vectors with improved transgene expression in a mouse skeletal muscle cell line and in primary human skeletal muscle cells","volume":"30","author":"Shoti","year":"2022","journal-title":"Mol. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"101147","DOI":"10.1016\/j.omtm.2023.101147","article-title":"Development of capsid- and genome-modified optimized AAVrh74 vectors for muscle gene therapy","volume":"31","author":"Shoti","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1089\/hum.2020.187","article-title":"AAV Vectors: Are They Safe?","volume":"31","author":"Srivastava","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.omtn.2023.05.014","article-title":"Rationale and strategies for the development of safe and effective optimized AAV vectors for human gene therapy","volume":"32","author":"Srivastava","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e0295725","DOI":"10.1128\/mbio.02957-25","article-title":"mGem: AAV, from almost a virus to an awesome vector-or is it?","volume":"17","author":"Srivastava","year":"2026","journal-title":"mBio"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.ymthe.2025.03.064","article-title":"AAV vector development, back to the future","volume":"33","author":"Song","year":"2025","journal-title":"Mol. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s11262-017-1502-7","article-title":"Next-generation AAV vectors for clinical use: An ever-accelerating race","volume":"53","author":"Weinmann","year":"2017","journal-title":"Virus Genes"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4694","DOI":"10.1016\/j.ymthe.2025.08.029","article-title":"The future of gene therapy: Safer vectors, sharper focus: High-profile failures demand deep root cause analysis\u2014But the transformative potential of AAV remains within reach if the field is willing to learn and evolve","volume":"33","author":"Chamberlain","year":"2025","journal-title":"Mol. Ther."},{"key":"ref_46","unstructured":"Fierce Pharma (2025). Sarepta Reports 2nd Death After DMD Gene Therapy Elevidys, Stops Dosing in Half of Patients, Fierce Pharma."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1089\/hum.2022.29216.bfs","article-title":"Novartis Confirms Deaths of Two Patients Treated with Gene Therapy Zolgensma","volume":"33","author":"Philippidis","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41434-025-00535-8","article-title":"Fatal outcomes following onasemnogene abeparvovec in advanced-stage spinal muscular atrophy","volume":"32","author":"Pongsakornkullachart","year":"2025","journal-title":"Gene Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/hum.2022.29198.bfs","article-title":"After Patient Death, FDA Places Hold on Pfizer Duchenne Muscular Dystrophy Gene Therapy Trial","volume":"33","author":"Philippidis","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1089\/hum.2024.38567.bfs","article-title":"Pfizer Weighs Next Steps after DMD Therapy Linked to Boy\u2019s Death Fails Phase III Trial","volume":"35","author":"Philippidis","year":"2024","journal-title":"Hum. Gene Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa2307798","article-title":"Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne\u2019s Muscular Dystrophy","volume":"389","author":"Lek","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_52","unstructured":"(2025, June 11). Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome. Available online: https:\/\/ir.neurogene.com\/news-releases\/news-release-details\/neurogene-provides-update-ngn-401-gene-therapy-clinical-trial."},{"key":"ref_53","unstructured":"Taylor, N.P. (2025, June 11). Rocket Crashes as Gene Therapy Patient Dies, FDA Imposes Hold. Available online: https:\/\/www.fiercebiotech.com\/biotech\/rocket-crashes-gene-therapy-patient-dies-fda-imposes-hold."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1016\/j.ymthe.2025.04.045","article-title":"Current clinical applications of AAV-mediated gene therapy","volume":"33","author":"Byrne","year":"2025","journal-title":"Mol. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Sender, R., Fuchs, S., and Milo, R. (2016). Revised Estimates for the Number of Human and Bacteria Cells in the Body. PLoS Biol., 14.","DOI":"10.1101\/036103"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"7196","DOI":"10.1128\/JVI.00493-16","article-title":"Mutants at the 2-Fold Interface of Adeno-associated Virus Type 2 (AAV2) Structural Proteins Suggest a Role in Viral Transcription for AAV Capsids","volume":"90","author":"Aydemir","year":"2016","journal-title":"J. Virol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1128\/JVI.02093-13","article-title":"Adeno-associated virus capsid proteins may play a role in transcription and second-strand synthesis of recombinant genomes","volume":"88","author":"Salganik","year":"2014","journal-title":"J. Virol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.virol.2020.04.008","article-title":"An essential N-terminal serine-rich motif in the AAV VP1 and VP2 subunits that may play a role in viral transcription","volume":"546","author":"Robinson","year":"2020","journal-title":"Virology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1089\/hum.2020.196","article-title":"Adeno-Associated Virus Capsid-Promoter Interactions in the Brain Translate from Rat to the Nonhuman Primate","volume":"31","author":"Bohlen","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.ymthe.2020.03.007","article-title":"AAV Capsid-Promoter Interactions Determine CNS Cell-Selective Gene Expression In Vivo","volume":"28","author":"Powell","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e0168124","DOI":"10.1128\/jvi.01681-24","article-title":"Adeno-associated virus 9 (AAV9) viral proteins VP1, VP2, and membrane-associated accessory protein (MAAP) differentially influence","volume":"98","author":"Powell","year":"2024","journal-title":"J. Virol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/4\/334\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T05:15:37Z","timestamp":1771046137000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/4\/334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":61,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["cells15040334"],"URL":"https:\/\/doi.org\/10.3390\/cells15040334","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]}}}